Cardiovascular risk biomarkers in CKD: the inflammation link and the road less traveled (Q38042361)

27 August 2017

Cardiovascular risk biomarkers in CKD: the inflammation link and the road less traveled (English)

1 reference

Maria Dolores Sanchez-niño

27 August 2017

0 references

object named as

Maria Dolores Sanchez-Niño

2

0 references

Alberto Ortiz

object named as

Alberto Ortiz

6

0 references

author name string

Usama Elewa

1

1 reference

27 August 2017

Catalina Martin-Cleary

3

1 reference

27 August 2017

Beatriz Fernandez-Fernandez

4

1 reference

27 August 2017

Jesus Egido

5

1 reference

27 August 2017

11 September 2012

1 reference

International Urology and Nephrology

27 August 2017

1 reference

27 August 2017

44

1 reference

27 August 2017

1731-1744

1 reference

27 August 2017

6

1 reference

Cardiovascular and noncardiovascular mortality among patients starting dialysis

27 August 2017

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

Clinical usefulness of novel prognostic biomarkers in patients on hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

Implementation of proteomic biomarkers: making it work

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

Monitoring of inflammation in patients on dialysis: forewarned is forearmed

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

Inflammation, atherosclerosis, and coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

KDOQI US commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

Atherosclerosis — An Inflammatory Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

Inflammation in peripheral artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

Chronic kidney disease: effects on the cardiovascular system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

Bidirectional relation between inflammation and coagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

Inflammation in atherosclerosis and implications for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

Fn14 is upregulated in cytokine-stimulated vascular smooth muscle cells and is expressed in human carotid atherosclerotic plaques: modulation by atorvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

Statins inhibit angiotensin II/Smad pathway and related vascular fibrosis, by a TGF-β-independent process.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

Essential role of TGF-beta/Smad pathway on statin dependent vascular smooth muscle cell regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

Oxidative stress and inflammation, a link between chronic kidney disease and cardiovascular disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

Inflammation and cardiovascular events in individuals with and without chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

Rosuvastatin for primary prevention among individuals with elevated high-sensitivity c-reactive protein and 5% to 10% and 10% to 20% 10-year risk. Implications of the Justification for Use of Statins in Prevention: an Intervention Trial Evaluating R

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

Cardiovascular risk in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

Interleukin-6 is a stronger predictor of total and cardiovascular mortality than C-reactive protein in haemodialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

Additive effects of soluble TWEAK and inflammation on mortality in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

Cytokine cooperation in renal tubular cell injury: the role of TWEAK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

The cytokine TWEAK modulates renal tubulointerstitial inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

TWEAK, a multifunctional cytokine in kidney injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

Nutrition in end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

Fetuin-A regulation of calcified matrix metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

FGF23 induces left ventricular hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

Serum alkaline phosphatase predicts mortality among maintenance hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

Pathophysiology of calcium and phosphate metabolism impairment in chronic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

Parathyroid Klotho and FGF-receptor 1 expression decline with renal function in hyperparathyroid patients with chronic kidney disease and kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

The need for reliable serum parathyroid hormone measurements

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

The expanding spectrum of biological actions of vitamin D.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

Vitamin D in patients with renal failure: a summary of observational mortality studies and steps moving forward

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

Globotriaosylsphingosine actions on human glomerular podocytes: implications for Fabry nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

Cholecalciferol supplementation alters calcitriol-responsive monocyte proteins and decreases inflammatory cytokines in ESRD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

Role of Klotho in aging, phosphate metabolism, and CKD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

Klotho deficiency causes vascular calcification in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

The inflammatory cytokines TWEAK and TNFα reduce renal klotho expression through NFκB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

Fibroblast growth factor 23 and Inflammation in CKD

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

Relation between alkaline phosphatase, serum phosphate, and all-cause or cardiovascular mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

Serum alkaline phosphatase levels associate with elevated serum C-reactive protein in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

Clinical outcomes with active versus nutritional vitamin D compounds in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

The effect of vitamin D derivatives on vascular calcification associated with inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

Progressive vascular calcification over 2 years is associated with arterial stiffening and increased mortality in patients with stages 4 and 5 chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

Asymmetrical dimethylarginine triggers lipolysis and inflammatory response via induction of endoplasmic reticulum stress in cultured adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

ADMA: a novel risk factor that explains excess cardiovascular event rate in patients with end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

Handling of asymmetrical dimethylarginine and symmetrical dimethylarginine by the rat kidney under basal conditions and during endotoxaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

Circulating levels of advanced glycation end products (AGE) and interleukin-6 (IL-6) are independent determinants of serum asymmetric dimethylarginine (ADMA) levels in patients with septic shock.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

Low triiodothyronine: a new facet of inflammation in end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

Induced illness in interleukin-6 (IL-6) knock-out mice: a causal role of IL-6 in the development of the low 3,5,3'-triiodothyronine syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

Effects of tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-6 on type I iodothyronine 5'-deiodination in rat thyroid cell line, FRTL-5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

Mechanisms behind the non-thyroidal illness syndrome: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

Selective consumption of thyroxine-binding globulin during cardiac bypass surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

Clinical and biochemical implications of low thyroid hormone levels (total and free forms) in euthyroid patients with chronic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

CCR5 deletion protects against inflammation-associated mortality in dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

Cytokine gene polymorphism and progression of renal and cardiovascular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

IL-1β receptor antagonist reduces inflammation in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

Actual status of antiinterleukin-1 therapies in rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

Safety and pharmacokinetics of subcutaneously administered rilonacept in patients with well-controlled end-stage renal disease (ESRD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

Renal cystic diseases and renal neoplasms: a mini-review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

Macrophages promote cyst growth in polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

Renal injury is a third hit promoting rapid development of adult polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

Pharmacokinetic and pharmacodynamic modeling of an anti-interleukin-6 chimeric monoclonal antibody (siltuximab) in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

Inflammation and Asymmetric Dimethylarginine for Predicting Death and Cardiovascular Events in ESRD Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

Inflammation Markers, Adhesion Molecules, and All-Cause and Cardiovascular Mortality in Patients with ESRD: Searching for the Best Risk Marker by Multivariate Modeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

Dissecting Inflammation in ESRD: Do Cytokines and C-Reactive Protein Have a Complementary Prognostic Value for Mortality in Dialysis Patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

Asymmetric dimethyl-arginine (ADMA) response to inflammation in acute infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

Low triiodothyronine and survival in end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-012-0271-4

Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease

21 January 2018

1 reference

12 December 2020

Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease

1 reference

12 December 2020

On the role of adjuvants in calciphylaxis

1 reference

12 December 2020

Relationship of the increased serum interleukin-6 concentration to changes of thyroid function in nonthyroidal illness

1 reference

12 December 2020

Beyond proteinuria: VDR activation reduces renal inflammation in experimental diabetic nephropathy

1 reference

12 December 2020

Prevention of vascular calcification: is pyrophosphate therapy a solution?

1 reference

12 December 2020

K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease

1 reference

12 December 2020

Alkalinization potentiates vascular calcium deposition in an uremic milieu

1 reference

12 December 2020

Serum alkaline phosphatase and mortality in hemodialysis patients.

1 reference

12 December 2020

The inhibitory effect of simvastatin on the ADMA-induced inflammatory reaction is mediated by MAPK pathways in endothelial cells

1 reference

12 December 2020

Fibroblast Growth Factor 23 (FGF23) Predicts Progression of Chronic Kidney Disease: The Mild to Moderate Kidney Disease (MMKD) Study

1 reference

12 December 2020

Inflammation markers, chronic kidney disease, and renal replacement therapy

1 reference

12 December 2020

Serum 25(OH)-vitamin D levels and bone metabolism in patients on maintenance hemodialysis

1 reference

12 December 2020

Lanthanum carbonate reduces FGF23 in chronic kidney disease Stage 3 patients

1 reference

12 December 2020

Multi-biomarker risk stratification of N-terminal pro-B-type natriuretic peptide, high-sensitivity C-reactive protein, and cardiac troponin T and I in end-stage renal disease for all-cause death

1 reference

12 December 2020

Trimestral variations of C-reactive protein, interleukin-6 and tumour necrosis factor- are similarly associated with survival in haemodialysis patients

1 reference

12 December 2020

Interleukin 6 inhibition - RA and beyond

1 reference

12 December 2020

Pentraxin 3: a novel biomarker for inflammatory cardiovascular disease

1 reference

12 December 2020

Bone Alkaline Phosphatase and Mortality in Dialysis Patients

1 reference

12 December 2020

Relation between serum interleukin-6 and thyroid hormone concentrations in 270 hospital in-patients with non-thyroidal illness

1 reference

12 December 2020

Partial hepatectomy and mediators of inflammation decrease the expression of liver alpha 2-HS glycoprotein gene in rats

1 reference

12 December 2020

The effect of etanercept on suppression of the systemic inflammatory response in chronic hemodialysis patients.

1 reference

12 December 2020

Plasma parathyroid hormone level and prevalent cardiovascular disease in CKD stages 3 and 4: an analysis from the Kidney Early Evaluation Program (KEEP)

1 reference

12 December 2020

10.1007/S11255-012-0271-4

Identifiers

DOI

1 reference

27 August 2017

1 reference